# Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE

> **NCT05649046** · NA · UNKNOWN · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 160 (actual)

## Conditions studied

- Smoking-related Pathology
- Atheroma
- Chronic Bronchitis
- Non-progressive Cancer > 5 Years
- Lung Cancer

## Interventions

- **DEVICE:** thoracic scan Low dose
- **BIOLOGICAL:** BLOOD SAMPLE
- **BIOLOGICAL:** FECES SAMPLE

## Key facts

- **NCT ID:** NCT05649046
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-23
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2024-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05649046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05649046, "Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05649046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*